This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Teicher, B. A. PubMed PubMed Citation Articles by Teicher, B. A. Related Collections Therapeutics and Targets Therapeutics and Targets: Experimental Therapeutics– Small Molecules

Newer Cytotoxic Agents: Attacking Cancer Broadly

Author's Affiliation: Genzyme Corporation, Framingham, Massachusetts

Requests for reprints: Beverly A. Teicher, Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701-9322. Phone: 508-271-2843; Fax: 508-620-1203; E-mail: Beverly.Teicher{at}Genzyme.com.

Abstract

The plasticity and instability of the cancer genome is impressive and is characterized by gene amplifications and deletions, rearrangements, and many silent and active mutations. Although targeted therapeutics have had effect in some diseases, there remains a large role for new cytotoxic agents that have the potential to be broadly active across multiple cancers. Platinum-based regimens are the basis for treatment of several common tumors. Satraplatin and picoplatin are newer platinum complexes that form bulkier lesions in DNA than their forerunners. Microtubules are a key target for anticancer agents. Vinca alkaloid and similar compounds fragment these critical structures, whereas taxanes stabilize them. Vinflunine is a new fluorinated Vinca alkaloid derivative with vascular disrupting effects, as well as antitumor effects. Epothilones are a new class of microtubule stabilizers. Mitosis has been targeted directly and indirectly by many anticancer agents. The aurora kinases are new targets in this class. Inhibitors of aurora kinases are likely to be cytotoxic. Finally, protein regulation is essential for cellular integrity. With the approval of bortezomib (Velcade, PS-341), the proteosome, a master protein regulator, has been validated as an anticancer target. The five articles in this issue of CCR Focus present the current status of these next generation cytotoxic agents.

This article has been cited by other articles:

				G. C. Prendergast Refining Cytotoxic Therapy: Progress in Generalized Therapeutics for Cancer Cancer Reviews Online Content, April 1, 2008; 2008(4): 7 - 7. [Full Text] [PDF]

				B. A. Teicher Newer Cytotoxic Agents: Attacking Cancer Broadly Clin. Cancer Res., March 15, 2008; 14(6): 1610 - 1617. [Abstract] [Full Text] [PDF]

				H. Choy, C. Park, and M. Yao Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue Clin. Cancer Res., March 15, 2008; 14(6): 1633 - 1638. [Abstract] [Full Text] [PDF]

				R. Z. Orlowski and D. J. Kuhn Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade Clin. Cancer Res., March 15, 2008; 14(6): 1649 - 1657. [Abstract] [Full Text] [PDF]